Health interventions costing as little as $2 per person could prevent hundreds of thousands of deaths from breast and cervical cancer in developing countries, scientists say.
Nearly 800,000 women die of cervical and breast cancer every year, with two thirds of breast cancer deaths and 9 out of 10 cervical cancer deaths in developing countries, they said in a study published in The Lancet medical journal.
While some diagnostic and treatment options such as mammography and radiotherapy are often not available in poor countries, several low-cost interventions have a potential to save lives, the scientists said.
"There is a widespread misconception that breast and cervical cancers are too difficult and expensive to prevent and treat, particularly in resource-poor countries where the burden of these diseases is highest," Ophira Ginsburg from the University of Toronto said in a statement.
"But nothing could be further from the truth. Recent estimates suggest that a basic cancer control package could be introduced in low- and middle-income countries for as little as $US1.72 ($A2.25) per person - equivalent to just 3 per cent of current health spending in these countries."
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Breast and cervical cancer kill nearly three times as many women each year than complications from pregnancy and childbirth, the scientists from University of Toronto, University of Cape Town and King's College London, said.
With the number of women diagnosed with breast cancer expected to almost double to 3.2 million in 2030 and the number of women diagnosed with cervical cancer projected to rise by at least a quarter to over 700,000, the scientists warned the cost of inaction will be "huge".
They said human papilloma virus (HPV) vaccination of girls in the world's poorest countries over a period of four years could prevent 600,000 deaths from cervical cancer.
Low- and middle- income countries receive just five per cent of global funding for cancer and persistent under-investment has exacerbated the problem.
